Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

Accomplished RNA therapeutics leader with track record of advancing novel genetic medicines from discovery to FDA approval to ...

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...

This study provides a comprehensive evaluation of the off-target effects of ADARdd and provides guidelines for improving RNA editing accuracy in plants. The authors also emphasize that ...

In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Last week, biotechnology company Ascidian Therapeutics announced a manufacturing partnership with gene-therapy–focused ...

The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...